The current therapeutics space in oncology is becoming dominated by the fast-emerging arsenal of immuno-oncology (I-O) therapies. CPABs targeting oncogenes or oncoproteins that are critical for tumor growth and progression are clearly differentiated and could therefore work alongside and complement I-O treatments, broadening the scope of novel cancer therapeutic regimens.
Current cancer treatments can be broadly classified as either antibodies or small molecules and are limited by the targets which they can address. Antibodies, whilst highly potent and specific, are limited to targets outside of the cell. Small molecules are able to reach the intracellular space, but their small interaction area limits the number of target types with which they can interact with sufficient potency and specificity. As a result, these conventional drug formats can only access less than 20% of all known disease targets.
CPABs overcome the limitations of current drugs through combining the advantageous potency and specificity of antibodies with the cell penetrating ability of small molecules. CPABs can access the cytosolic and intranuclear space, both of which contain many regulatory targets (proteins, DNA, transcription factors etc.) essential to cancer growth and thus representing a rich repository of important new therapeutic targets.
The CPAB platform has the potential to generate novel cancer therapies with blockbuster potential based on the ability of CPABs to interact with the key molecular elements that are part of essential oncogenic pathways active inside cancer cells.
The Company believes that, thanks to their unique capacity to address a broad universe of intractable oncogenic targets, CPABs represent an entirely novel class of therapeutics that have the potential to significantly improve treatment outcomes for cancer patients.